Addressing Concerns of Vitamin D Deficiency

Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

The FDA approved several drugs in December for the treatment of diseases, including pancreatic adenocarcinoma, lung cancer, skin cancer and graft-versus-host disease.

CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.

Opdivo Qvantig received FDA approval for all previously approved indications in solid tumors.

This Christmas, my wish for all of you is that you read this and feel seen, that someone out there knows how very hard this is for you.